AGEN

SEC source: 0000899243-22-013872 · doc4.xml · nonDerivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,382

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive her director fees in shares of Agenus' common stock.

F2 · price: $2.753 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0000899243-22-013870 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,997.393

Underlying: Common Stock · 9,307.809 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.753 per Deferred Stock Unit acquired on April 1, 2022. The price of each Deferred Stock Unit acquired prior to April 1, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-22-013868 · doc4.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,648.811

Underlying: Common Stock · 9,534.829 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $2.753 per Deferred Stock Unit acquired on April 1, 2022. The price of each Deferred Stock Unit acquired prior to April 1, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-22-005244 · doc4.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

SEC source: 0000899243-22-005243 · doc4.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

SEC source: 0000899243-22-005255 · doc4.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

SEC source: 0000899243-22-005241 · doc4.xml · derivative · entry 1

Jeynes-Ellis Allison M · CIK 0001758521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

SEC source: 0000899243-22-005239 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

SEC source: 0000899243-22-005238 · doc4.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023.

SEC source: 0000899243-22-004867 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,007,784

F1 · security: Reflects the executive's 2021 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 6-month lockup restriction with 25% of the award released on the 3-month anniversary of the issuance date and 75% of the award released on the 6-month anniversary.

F2 · price: $2.51 was the fair market value of our Common Stock on February 2, 2022, the stock issuance date.

SEC source: 0000899243-22-004869 · doc4.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,003

F1 · security: Reflects the executive's 2021 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 6-month lockup restriction with 25% of the award released on the 3-month anniversary of the issuance date and 75% of the award released on the 6-month anniversary.

F2 · price: $2.51 was the fair market value of our Common Stock on February 2, 2022, the stock issuance date.

SEC source: 0000899243-22-004868 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,643

F1 · security: Reflects the executive's 2021 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 6-month lockup restriction with 25% of the award released on the 3-month anniversary of the issuance date and 75% of the award released on the 6-month anniversary.

F2 · price: $2.51 was the fair market value of our Common Stock on February 2, 2022, the stock issuance date.

SEC source: 0000899243-22-001245 · doc4.xml · nonDerivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,321

F2 · kind: Represents sales of shares, as a consequence of the vesting of restricted stock units, to cover Federal, state and local tax withholding requirements related to the vesting. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.055 to $3.065. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-001245 · doc4.xml · derivative · entry 3

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On January 4, 2021, the reporting person was granted 100,000 restricted stock units that fully vested on January 4, 2022.

F3 · derivative.expiration_date: On January 4, 2021, the reporting person was granted 100,000 restricted stock units that fully vested on January 4, 2022.

SEC source: 0000899243-22-001245 · doc4.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000899243-22-000867 · doc4.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,113.982

Underlying: Common Stock · 6,547.893 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $4.009 per Deferred Stock Unit acquired on January 3, 2022. The price of each Deferred Stock Unit acquired prior to January 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F2 · derivative.expiration_date: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

SEC source: 0000899243-22-000866 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,689.584

Underlying: Common Stock · 6,391.991 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $4.009 per Deferred Stock Unit acquired on January 3, 2022. The price of each Deferred Stock Unit acquired prior to January 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-22-000853 · doc4.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,895.4

Underlying: Common Stock · 2,338.533 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $4.009 per Deferred Stock Unit acquired on January 3, 2022. The price of each Deferred Stock Unit acquired prior to January 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-22-000851 · doc4.xml · nonDerivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,571

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive her director fees in shares of Agenus' common stock.

F2 · price: $4.009 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0000899243-22-000599 · doc4.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900,000

Underlying: Common Stock · 1,900,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: One-third of the stock options vest on the one-year anniversary of the date of grant, with the remainder vesting in equal quarterly installments thereafter; provided that the Reporting Person maintains a service relationship with the Issuer through each such vesting date.

SEC source: 0000899243-22-000624 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: One-third of the stock options vest on the one-year anniversary of the date of grant, with the remainder vesting in equal quarterly installments thereafter; provided that the Reporting Person maintains a service relationship with the Issuer through each such vesting date.

SEC source: 0000899243-22-000598 · doc4.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2022-01-02

F1 · derivative.exercise_date: One-third of the stock options vest on the one-year anniversary of the date of grant, with the remainder vesting in equal quarterly installments thereafter; provided that the Reporting Person maintains a service relationship with the Issuer through each such vesting date.

SEC source: 0000899243-21-039314 · doc4.xml · derivative · entry 1

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,566.089

Underlying: Common Stock · 4,559.889 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $5.757 per Deferred Stock Unit acquired on October 1, 2021. The price of each Deferred Stock Unit acquired prior to October 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-21-039313 · doc4.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,556.867

Underlying: Common Stock · 1,628.532 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $5.757 per Deferred Stock Unit acquired on October 1, 2021. The price of each Deferred Stock Unit acquired prior to October 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-21-039312 · doc4.xml · nonDerivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,894

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive her director fees in shares of Agenus' common stock.

F2 · price: $5.757 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0000899243-21-039305 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,297.593

Underlying: Common Stock · 4,451.32 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $5.757 per Deferred Stock Unit acquired on October 1, 2021. The price of each Deferred Stock Unit acquired prior to October 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-21-035844 · doc4.xml · derivative · entry 5

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 119,178 shares

Expires 2021-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035844 · doc4.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 770,773

F4 · price: Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035844 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 852,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.

SEC source: 0000899243-21-035843 · doc4.xml · derivative · entry 3

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,563 shares

Expires 2021-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035843 · doc4.xml · nonDerivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,056

F3 · price: Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.47 to $6.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035843 · doc4.xml · nonDerivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.

F2 · balance_after: The number of shares beneficially owned by the reporting person does not reflect 998 shares that were incorrectly reported on prior Form 4s.

SEC source: 0000899243-21-027363 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 733,702

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 2, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $5.52 is the closing price of our Common Stock on July 2, 2021, the payroll date for the pay period ending July 2, 2021.

SEC source: 0000899243-21-027354 · doc4.xml · nonDerivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,637

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive her director fees in shares of Agenus' common stock.

F2 · price: $3.820 is the is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0000899243-21-027312 · doc4.xml · derivative · entry 2

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,846.273

Underlying: Common Stock · 6,707.279 shares

Expires not disclosed

F2 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F4 · price: $3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F3 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F3 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-21-027301 · doc4.xml · derivative · entry 2

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,928.335

Underlying: Common Stock · 2,453.883 shares

Expires not disclosed

F2 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F4 · price: $3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan

F3 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F3 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-21-027295 · doc4.xml · derivative · entry 2

JORDAN WADIH · CIK 0001222090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,006.2

Underlying: Common Stock · 6,870.871 shares

Expires not disclosed

F2 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F4 · price: $3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F3 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F3 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000899243-21-027356 · doc4.xml · nonDerivative · entry 1

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,091

F1 · security: The stock issued is fully-vested on the date of issuance, but is subject to a 12-month lockup restriction.

SEC source: 0000899243-21-025019 · doc4.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,023

F1 · security: As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 14, 2021, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the first half of 2021. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 18, 2021. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $5.26 is the closing price of our Common Stock on June 18, 2021, the payroll date for the pay period ending June 18, 2021.

SEC source: 0000899243-21-025084 · doc4.xml · derivative · entry 2

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 16, 2021, Mr. Corvese was granted 16,000 Restricted Stock Unit as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Corvese's continued service on the Board of Directors through such date.

F2 · shares: On June 16, 2021, Mr. Corvese was granted 16,000 Restricted Stock Unit as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Corvese's continued service on the Board of Directors through such date.

F2 · price: On June 16, 2021, Mr. Corvese was granted 16,000 Restricted Stock Unit as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Corvese's continued service on the Board of Directors through such date.

F2 · derivative.exercise_date: On June 16, 2021, Mr. Corvese was granted 16,000 Restricted Stock Unit as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Corvese's continued service on the Board of Directors through such date.

F2 · derivative.expiration_date: On June 16, 2021, Mr. Corvese was granted 16,000 Restricted Stock Unit as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Corvese's continued service on the Board of Directors through such date.

SEC source: 0000899243-21-025084 · doc4.xml · nonDerivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,085

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 16, 2020, Mr. Corvese was granted 22,471 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Corvese was issued the underlying 22,471 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 16, 2020, Mr. Corvese was granted 22,471 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Corvese was issued the underlying 22,471 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

SEC source: 0000899243-21-025024 · doc4.xml · nonDerivative · entry 1

Jeynes-Ellis Allison M · CIK 0001758521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 16, 2020, Ms. Jeynes-Ellis was granted 16,853 Restricted Stock Units as part of her annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Ms. Jeynes-Ellis was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 16, 2020, Ms. Jeynes-Ellis was granted 16,853 Restricted Stock Units as part of her annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Ms. Jeynes-Ellis was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

SEC source: 0000899243-21-025015 · doc4.xml · derivative · entry 3

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,501

Underlying: Common Stock · 20,501 shares

Expires 2031-06-16

F3 · security: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

SEC source: 0000899243-21-025015 · doc4.xml · derivative · entry 2

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires not disclosed

F2 · derivative.exercise_price: On June 16, 2021, Mr. Wright was granted 12,000 Restricted Stock Unitsas part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Wright's continued service on the Board of Directors through such date.

F2 · shares: On June 16, 2021, Mr. Wright was granted 12,000 Restricted Stock Unitsas part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Wright's continued service on the Board of Directors through such date.

F2 · price: On June 16, 2021, Mr. Wright was granted 12,000 Restricted Stock Unitsas part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Wright's continued service on the Board of Directors through such date.

F2 · derivative.exercise_date: On June 16, 2021, Mr. Wright was granted 12,000 Restricted Stock Unitsas part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Wright's continued service on the Board of Directors through such date.

F2 · derivative.expiration_date: On June 16, 2021, Mr. Wright was granted 12,000 Restricted Stock Unitsas part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The award vests in full on June 16, 2022, subject to Mr. Wright's continued service on the Board of Directors through such date.

SEC source: 0000899243-21-025015 · doc4.xml · nonDerivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 16, 2020, Mr. Wright was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wright was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 16, 2020, Mr. Wright was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wright was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

SEC source: 0000899243-21-024971 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 16, 2020, Mr. Wiinberg was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wiinberg was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

F1 · price: On June 16, 2020, Mr. Wiinberg was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wiinberg was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan.

SEC source: 0000899243-21-027363 · doc4.xml · derivative · entry 4

ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,900,000

Underlying: Common Stock · 1,900,000 shares

Expires 2030-12-17

F5 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.

SEC source: 0000899243-21-027356 · doc4.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · COO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2030-12-17

F2 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.

SEC source: 0000899243-21-027354 · doc4.xml · derivative · entry 2

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-12-17

F3 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022.

SEC source: 0000899243-21-027316 · doc4.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-12-17

F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests over a four-year period, with 1/3 of Option vesting on December 17, 2022, and the balance vesting in eight equal quarterly installments thereafter.